Nextech V Oncology S.C.S. SICAV-SIF 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:16 pm Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 0 0.000% |
-2,329,480 (Position Closed) |
Filing |
| 2023-02-14 4:32 pm Sale |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 2,329,480 5.300% |
-678,763 (-22.56%) |
Filing |
| 2021-02-16 4:00 pm Purchase |
2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 3,008,243 6.900% |
3,008,243 (New Position) |
Filing |